JSH-23 is a small molecule NF-κB inhibitor, inhibits NF-κB transcriptional activity with IC50 of 7.1 uM in LPS-stimulated macrophages RAW 264.7.
JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation.
JSH-23 (<100 uM) does not show significant cytotoxic effects on the RAW 264.7 cells.
JSH-23 (1 mg/kg, 3 mg/kg; oral daily for 2 weeks) significantly reverses the nerve conduction and nerve blood flow deficits seen in diabetic rats.
Physicochemical Properties
M.Wt
240.35
Formula
C16H20N2
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
4-Methyl-N1-(3-phenylpropyl)benzene-1,2-diamine
References
1. Shin HM, et al. FEBS Lett. 2004 Jul 30;571(1-3):50-4.
2. Kumar A, et al. Diabetes Obes Metab. 2011 Aug;13(8):750-8.
